首页> 外文期刊>Trials >Update on the endorsement of CONSORT by high impact factor journals: a survey of journal “Instructions to Authors” in 2014
【24h】

Update on the endorsement of CONSORT by high impact factor journals: a survey of journal “Instructions to Authors” in 2014

机译:高影响因子期刊对CONSORT认可的最新信息:2014年对“作者须知”期刊的调查

获取原文
           

摘要

Background The CONsolidated Standards Of Reporting Trials (CONSORT) Statement provides a minimum standard set of items to be reported in published clinical trials; it has received widespread recognition within the biomedical publishing community. This research aims to provide an update on the endorsement of CONSORT by high impact medical journals. Methods We performed a cross-sectional examination of the online “Instructions to Authors” of 168 high impact factor (2012) biomedical journals between July and December 2014. We assessed whether the text of the “Instructions to Authors” mentioned the CONSORT Statement and any CONSORT extensions, and we quantified the extent and nature of the journals’ endorsements of these. These data were described by frequencies. We also determined whether journals mentioned?trial registration and the International Committee of Medical Journal Editors (ICMJE; other than in regards to trial registration) and whether either of these was associated with CONSORT endorsement (relative risk and 95?% confidence interval). We compared our findings to the two previous iterations of this survey (in 2003 and 2007). We also identified the publishers of the included journals. Results Sixty-three percent (106/168) of the included journals mentioned CONSORT in their “Instructions to Authors.” Forty-four endorsers (42?%) explicitly stated that authors “must” use CONSORT to prepare their trial manuscript, 38?% required an accompanying completed CONSORT checklist as a condition of submission, and 39?% explicitly requested the inclusion of a flow diagram with the submission. CONSORT extensions were endorsed by very few journals. One hundred and thirty journals (77?%) mentioned ICMJE, and 106 (63?%) mentioned trial registration. Conclusions The endorsement of CONSORT by high impact journals has increased over time; however, specific instructions on how CONSORT should be used by authors are inconsistent across journals and publishers. Publishers and journals should encourage authors to use CONSORT and set clear expectations for authors about compliance with CONSORT.
机译:背景合并报告标准草案(CONSORT)声明提供了在已发表的临床试验中报告的最低标准项目集。它在生物医学出版界得到了广泛认可。这项研究旨在提供有关高影响力医学期刊对CONSORT认可的最新信息。方法我们对2014年7月至2014年12月之间的168篇高影响因子(2012)生物医学期刊的在线“作者说明”进行了横断面检查。我们评估了“作者说明”的文本中是否提及CONSORT声明以及任何CONSORT扩展,我们量化了这些期刊认可的范围和性质。这些数据用频率描述。我们还确定了期刊是否提到了试验注册和国际医学期刊编辑委员会(ICMJE;关于试验注册除外),以及这些期刊是否都与CONSORT认可有关(相对风险和95%置信区间)。我们将调查结果与本次调查的前两次迭代(在2003年和2007年)进行了比较。我们还确定了所包括期刊的出版商。结果收录的期刊中有63%(106/168)在其“作者须知”中提到CONSORT。四十四名背书人(42%)明确指出,作者“必须”使用CONSORT来准备其试验手稿,38 %%的人要求随附随附的完整CONSORT检查表作为提交条件,而39 %%的人明确要求包括流程提交图。 CONSORT扩展得到了很少的期刊的认可。一百三十种期刊(77%)提到了ICMJE,而106种期刊(63 %%)提到了试用注册。结论随着时间的推移,高影响力期刊对CONSORT的认可有所增加。但是,关于期刊作者应如何使用CONSORT的具体说明在期刊和出版商之间并不一致。出版商和期刊应鼓励作者使用CONSORT,并为作者明确遵守CONSORT的期望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号